Establishment and characterization of a docetaxel‑resistant human prostate cancer cell line

Liu,Jian; Huang,Yujie; Zhu,Danyan; Dai,Yao; Liu,Dan; Zhai,You; Liang,Xingguang; Wu,Lihua; Zhao,Qingwei

doi:10.3892/ol.2020.12093

November-2020 Volume 20 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2020 Volume 20 Issue 5

Full Size Image

Article Open Access

Establishment and characterization of a docetaxel‑resistant human prostate cancer cell line

Authors:
- Jian Liu
- Yujie Huang
- Danyan Zhu
- Yao Dai
- Dan Liu
- You Zhai
- Xingguang Liang
- Lihua Wu
- Qingwei Zhao
View Affiliations / Copyright

Affiliations: Research Center for Clinical Pharmacy, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China, Department of Radiation Oncology, College of Medicine, University of Florida, Florida, FL 32610, USA, Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China

Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 230
|
Published online on: September 11, 2020

https://doi.org/10.3892/ol.2020.12093
Expand metrics +

Abstract

The aim of the present study was to establish a novel docetaxel‑resistant prostate cancer cell line and investigate its biological characteristics. The human prostate cell line, PC‑3, was exposed to docetaxel, the concentrations of which were increased in a stepwise manner in the medium to select the drug‑resistant cell line, PC‑3/DTX. The morphological features were observed using inverted microscopy. The growth curves of PC‑3 and PC‑3/DTX cells were drawn to calculate the doubling time. Flow cytometry was performed to determine cell‑cycle distribution. A 3‑(4,5‑dimethyl‑2‑thiazol)-2,5‑diphenyl‑2H tetrazolium bromide assay was performed to test the drug resistance of PC‑3 and PC‑3/DTX cells. Western blot analysis was conducted to determine the protein expression levels of the mammalian target of rapamycin (mTOR) signaling pathway, which may serve a role in regulating drug resistance in the two cell lines. PC‑3/DTX cells exhibited changes in morphology, proliferation rate, doubling time and cell‑cycle distributions, compared with PC‑3 cells. PC‑3/DTX cells were 10.9‑fold resistant to docetaxel in comparison with PC‑3 cells. The results showed that PC‑3/DTX cells overexpressed Rictor and p‑AKT(S473) proteins, which are specific subunits or downstream substrates of mTORC2. The new findings suggested that the mTORC2 signaling pathway may serve an important role in the regulation of docetaxel drug resistance of PC‑3 cells. In conclusion, PC‑3/DTX cells may be applied to study the resistance of anticancer drugs and to identify methods to overcome resistance.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
3	Pagliarulo V: Androgen deprivation therapy for prostate cancer. Adv Exp Med Biol. 1096:1–30. 2018. View Article : Google Scholar : PubMed/NCBI
4	Pienta KJ and Bradley D: Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res. 12:1665–1671. 2006. View Article : Google Scholar : PubMed/NCBI
5	Seruga B, Ocana A and Tannock IF: Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 8:12–23. 2011. View Article : Google Scholar : PubMed/NCBI
6	Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
7	Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
8	Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E and Oya M: Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. J Urol. 185:2376–2381. 2011. View Article : Google Scholar : PubMed/NCBI
9	Morgan TM, Koreckij TD and Corey E: Targeted therapy for advanced prostate cancer: Inhibition ofthe PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 9:237–249. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, et al: A co-clinical approach identifies mechanisms andpotential therapiesfor androgen deprivation resistance in prostate cancer. Nat Genet. 45:747–755. 2013. View Article : Google Scholar : PubMed/NCBI
11	Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG and Wu H: Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 19:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
12	Zoncu R, Efeyan A and Sabatini DM: mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 12:21–35. 2011. View Article : Google Scholar : PubMed/NCBI
13	Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C and Pandolfi PP: Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev. 22:2172–2177. 2008. View Article : Google Scholar : PubMed/NCBI
14	Clohessy JG, Reschke M and Pandolfi PP: Found in translation of mTOR signaling. Cell Res. 22:1315–1318. 2012. View Article : Google Scholar : PubMed/NCBI
15	Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS and Sabatini DM: Aunifying model for mTORC1-mediated regulation of mRNA translation. Nature. 485:109–116. 2012. View Article : Google Scholar : PubMed/NCBI
16	Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, et al: The translationallandscape of mTOR signalling steers cancer initiation and metastasis. Nature. 485:55–64. 2012. View Article : Google Scholar : PubMed/NCBI
17	Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H and Sabatini DM: mTOR complex 2 is required for the development ofprostate cancer induced by Pten loss in mice. Cancer Cell. 15:148–159. 2009. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Establishment and characterization of a docetaxel‑resistant human prostate cancer cell line

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles